SR One

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

SR One

- Life Sciences
srone.com
Update Information

More venture news

Breedr
26 Aug 2026
Breedr unlocks £20m Series B led by Partech to digitalise the global cattle supply chain
Series BAgriculture
Olix
3 Aug 2026
OLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production
Series BDeep Tech
Mironid
5 Aug 2026
Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences

SR One

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Breedr unlocks £20m Series B led by Partech to digitalise the global cattle supply chain

OLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production

Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases